Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 2/20 | 0.38 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.38 |
| ▸ | PRKCG | P05129 | 1/20 | 0.38 |
| ▸ | PRKCB | P05771 | 1/20 | 0.38 |
| ▸ | PRKCH | P24723 | 1/20 | 0.38 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.38 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.38 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.38 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.38 |
| ▸ | DAGLA | Q9Y4D2 | 10/20 | 0.38 |
| ▸ | CNR1 | P21554 | 8/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | DAGLB | Q8NCG7 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | ABHD16A | O95870 | 1/20 | 0.35 |
| ▸ | LPL | P06858 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | LIPC | P11150 | 1/20 | 0.35 |
| ▸ | PNLIP | P16233 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9224189 | 1.00 | PRKCA (0.38) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| Antibiotic 1233A SCHEMBL613745 | 0.83 | PRKCA (0.35) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| Antibiotic 1233A SCHEMBL285679 | 0.83 | PRKCA (0.35) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| Antibiotic 1233A SCHEMBL285680 | 0.83 | PRKCA (0.35) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| SCHEMBL6061849 | 0.82 | PRKCA (0.40) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| SCHEMBL10368015 | 0.74 | DAGLA (0.34) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| SCHEMBL10368014 | 0.74 | DAGLA (0.34) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| SCHEMBL10367940 | 0.72 | PRKCA (0.41) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| SCHEMBL9576484 | 0.72 | DAGLA (0.35) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| SCHEMBL9576485 | 0.72 | DAGLA (0.35) | PRKCAPRKD3PRKCGPRKCBPRKCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1593670-B1 | Hydroxy-substituted 2-azetidinones useful as hypocholesterolemic agents | SCHERING CORP (US) | 2007-08-08 | — | — | EP | disclosed |
| EP-1593670-A1 | Hydroxy-substituted 2-azetidinones useful as hypocholesterolemic agents | Schering Corporation (US) | 2005-11-09 | — | — | EP | disclosed |
| EP-1510521-A1 | Sugar-substituted 2-Azetidinones useful as hypocholesterolemic agents | Schering Corporation (US) | 2005-03-02 | — | — | EP | disclosed |
| EP-1347987-B1 | SUGAR-SUBSTITUTED 2-AZETIDINONES USEFUL AS HYPOCHOLESTEROLEMIC AGENTS | SCHERING CORP (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20020137690-A1 | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents | SCHERING CORPORATION | 2002-09-26 | — | — | US | disclosed |
| EP-0877750-B1 | SUGAR-SUBSTITUTED 2-AZETIDINONES USEFUL AS HYPOCHOLESTEROLEMIC A GENTS | SCHERING CORP (US) | 2002-06-19 | — | — | EP | disclosed |
| EP-0869942-B1 | 4-((HETEROCYCLOALKYL OR HETEROAROMATIC)-SUBSTITUTED PHENYL]-2-AZETIDINONES USEFUL AS HYPOLIPIDEMIC AGENTS | SCHERING CORP (US) | 2002-02-13 | — | — | EP | disclosed |
| EP-0681569-B1 | SPIROCYCLOALKYL-SUBSTITUTED AZETIDINONES USEFUL AS HYPOCHOLESTEROLEMIC AGENTS | SCHERING CORP (US) | 2001-03-21 | — | — | EP | disclosed |
| EP-0751934-B1 | SUBSTITUTED AZETIDINONE COMPOUNDS USEFUL AS HYPOCHOLESTEROLEMIC AGENTS | SCHERING CORP (US) | 1999-08-25 | — | — | EP | disclosed |
| EP-0675714-B1 | COMBINATION OF A CHOLESTEROL BIOSYNTHESIS INHIBITOR AND A $g(b)-LACTAM CHOLESTEROL ABSORPTION INHIBITOR | SCHERING CORP (US) | 1999-01-20 | — | — | EP | disclosed |
| US-5661145-A | TREATING OR PREVENTING ATHEROSCLEROSIS OR REDUCING PLASMA CHOLESTEROL LEVELS | SCHERING CORPORATION (US) | 1997-08-26 | — | — | US | disclosed |
| US-5656624-A | ADMINISTERING TO LOWER SERUM CHOLESTEROL LEVELS | SCHERING CORPORATION (US) | 1997-08-12 | — | — | US | disclosed |
| US-5627176-A | MIXED WITH CHOLESTEROL BIOSYNTHESIS INHIBITOR; PREVENTING ATHEROSCLEROSIS | SCHERING CORPORATION (US) | 1997-05-06 | — | — | US | disclosed |
| EP-0751934-A1 | SUBSTITUTED AZETIDINONE COMPOUNDS USEFUL AS HYPOCHOLESTEROLEMIC AGENTS | SCHERING CORPORATION (US) | 1997-01-08 | — | — | EP | disclosed |
| WO-1995026334-A1 | SUBSTITUTED AZETIDINONE COMPOUNDS USEFUL AS HYPOCHOLESTEROLEMIC AGENTS | SCHERING CORPORATION (US) | 1995-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137690-A1 | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents | CYP46A1, PCSK9, SREBF2 | PRKCA 1249/4885PRKD3 1131/4885PRKCG 1963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.